tiprankstipranks
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
US Market
BMRN
BioMarin Pharmaceutical
RESEARCH TOOLSreports

BioMarin Pharmaceutical (BMRN) Stock News & Sentiment

2,390 Followers
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
Premium
Company Announcements
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
23d ago
BMRN
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
Premium
Ratings
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
25d ago
BMRN
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
Premium
Company Announcements
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
25d ago
8K
BMRN
BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
Premium
Ratings
BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
1M ago
BMRN
BioMarin Earnings Call Highlights Growth, Pipeline, Deals
Premium
Company Announcements
BioMarin Earnings Call Highlights Growth, Pipeline, Deals
1M ago
BMRN
BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating
Premium
Ratings
BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating
2M ago
BMRN
BioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
Premium
Ratings
BioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
2M ago
BMRN
More BMRN News >

BMRN News on the Web

RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)
TipRanks News
Bearish
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
Zacks
Neutral
How CNBC Cures is bringing rare disease stories to a national audience
CNBC
Neutral
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS)
TipRanks News
Bullish
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
TipRanks News
Neutral
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
TipRanks News
Bearish
BioMarin (BMRN) Halts Phase 2 Trials for Voxzogo Amid Safety Concerns
GuruFocus News
Bearish

News Score - Last 7 Days

Negative
BMRN
Sector Average
Media Buzz
This Week1 articles
Weekly Average2.75 articles
News Sentiment
This Week0%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BMRN’s Media Buzz Sentiment?
1 articles about BMRN were published this week. In an average week, 2.75 articles are published.
    What is BMRN’s weekly average amount of articles?
    In an average week, 2.75 articles about BMRN are published.
      What is BMRN’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      AORTArtivion
      NBIXNeurocrine
      STAAStaar Surgical
      SLPSimulations Plus
      OWLTOwlet
      Showing the stocks with the most bullish news sentiment over the past week